Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Verstovsek · SciRah

Researcher profile · Semantic Scholar

S. Verstovsek

Share profile

S. Verstovsek — researcher profile on SciRah

h-index: 111
Works: 1,531
Citations: 59K

Most-cited papers

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
S. Verstovsek, A. Gerds, A. Vannucchi, H. Al-Ali +23 more
2023The Lancet160 citations
Semantic Scholar
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
C. Harrison, Jacqueline S. Garcia, T. Somervaille, J. Foran +15 more
2022Journal of Clinical Oncology108 citations Open access
Semantic Scholar
Momelotinib: an emerging treatment for myelofibrosis patients with anemia
H. Chifotides, P. Bose, S. Verstovsek
2022Journal of Hematology & Oncology85 citations Open access
Semantic Scholar
Clinical development and management of adverse events associated with FGFR inhibitors
V. Subbiah, S. Verstovsek
2023Cell Reports Medicine78 citations Open access
Semantic Scholar
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
J. Mascarenhas, M. Kremyanskaya, A. Patriarca, F. Palandri +20 more
2023Journal of Clinical Oncology72 citations Open access
Semantic Scholar
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
S. Verstovsek, R. Mesa, R. Livingston, Wilson Hu +1 more
2023Journal of Hematology & Oncology60 citations Open access
Semantic Scholar
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
S. Verstovsek, R. Mesa, V MNSSVKR GUPTA, D. Lavie +16 more
2023Blood Advances52 citations Open access
Semantic Scholar
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
M. Kremyanskaya, Andrew T. Kuykendall, N. Pemmaraju, Ellen Ritchie +15 more
2024New England Journal of Medicine47 citations
Semantic Scholar
Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy
N. Pemmaraju, P. Bose, R. Rampal, A. Gerds +2 more
2023Leukemia and Lymphoma45 citations Open access
Semantic Scholar
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
C. Harrison, V MNSSVKR GUPTA, A. Gerds, R. Rampal +21 more
2022Future Oncology40 citations Open access
Semantic Scholar
Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
S. Verstovsek, I. Krečak, F. Heidel, V. De Stefano +11 more
2023Biomedicines31 citations Open access
Semantic Scholar
Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies
S. Verstovsek, J. Kiladjian, A. Vannucchi, R. Mesa +3 more
2023Cancer31 citations Open access
Semantic Scholar
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
A. Gerds, S. Verstovsek, A. Vannucchi, H. Al-Ali +24 more
2023The Lancet Haematology30 citations
Semantic Scholar
Interferons in the treatment of myeloproliferative neoplasms
P. Vachhani, J. Mascarenhas, P. Bose, Gabriela S. Hobbs +8 more
2024Therapeutic Advances in Hematology28 citations Open access
Semantic Scholar
Real-world treatments and thrombotic events in polycythemia vera patients in the USA
S. Verstovsek, N. Pemmaraju, N. Reaven, S. Funk +3 more
2023Annals of Hematology26 citations Open access
Semantic Scholar
Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
H. Chifotides, S. Verstovsek, P. Bose
2023Cancers21 citations Open access
Semantic Scholar
Momelotinib reduces transfusion requirements in patients with myelofibrosis
R. Mesa, Stephen T. Oh, A. Gerds, V. Gupta +15 more
2022Leukemia and Lymphoma20 citations Open access
Semantic Scholar
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
R. Mesa, C. Harrison, Jeanne M. Palmer, V. Gupta +17 more
2023HemaSphere19 citations Open access
Semantic Scholar
Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis
J. Mascarenhas, V. Popov, S. Mohan, Z. N. Özkurt +9 more
2024Blood18 citations Open access
Semantic Scholar
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM
L. Masarova, S. Verstovsek, T. Liu, Sumati Rao +8 more
2024Future Oncology18 citations Open access
Semantic Scholar
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial
S. Verstovsek, L. Foltz, V MNSSVKR GUPTA, R. Hasserjian +16 more
2023Haematologica18 citations Open access
Semantic Scholar
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study
P. Bose, L. Masarova, N. Pemmaraju, S. Bledsoe +20 more
2024Haematologica17 citations Open access
Semantic Scholar
Cytopenic myelofibrosis: prevalence, relevance, and treatment
P. Vachhani, S. Verstovsek, P. Bose
2023Expert Opinion on Pharmacotherapy17 citations
Semantic Scholar
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
Stephen T. Oh, S. Verstovsek, Vikas Gupta, U. Platzbecker +14 more
2024eJHaem15 citations Open access
Semantic Scholar
How I manage anemia related to myelofibrosis and its treatment regimens
S. Verstovsek
2023Annals of Hematology15 citations Open access
Semantic Scholar
A review of essential thrombocythemia and its complications.
R. Babakhanlou, L. Masarova, S. Verstovsek
2023Clinical advances in hematology & oncology : H&O15 citations
Semantic Scholar
Secondary erythrocytosis
R. Babakhanlou, S. Verstovsek, N. Pemmaraju, C. Rojas-Hernandez
2023Expert Review of Hematology14 citations
Semantic Scholar
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
J. Kiladjian, A. Vannucchi, A. Gerds, V. Gupta +16 more
2023HemaSphere14 citations Open access
Semantic Scholar
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
R. Mesa, S. Hudgens, L. Floden, C. Harrison +17 more
2023Cancer Medicine13 citations Open access
Semantic Scholar
Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.
Yahya A. Al-Ghamdi, Jonathan I Lake, A. Bagg, B. Thakral +17 more
2023Modern Pathology12 citations Open access
Semantic Scholar
S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
J. Mascarenhas, Tania Jain, Salman Otoukesh, A. Gerds +18 more
2023HemaSphere12 citations Open access
Semantic Scholar
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib
R. Mesa, S. Verstovsek, U. Platzbecker, V MNSSVKR GUPTA +20 more
2023Haematologica11 citations Open access
Semantic Scholar
Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
V MNSSVKR GUPTA, J. Mascarenhas, M. Kremyanskaya, R. Rampal +7 more
2023Blood Advances11 citations Open access
Semantic Scholar
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.
A. Gerds, C. Harrison, J. Kiladjian, R. Mesa +15 more
2023Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis
L. Masarova, S. Verstovsek, F. Palandri, R. Mesa +8 more
2025Future Oncology9 citations Open access
Semantic Scholar
Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes.
T. Kadia, Meixian Huang, N. Pemmaraju, H. Abbas +18 more
2024NEJM Evidence9 citations
Semantic Scholar
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
A. Gerds, Jing-Bo Yu, R. Scherber, Dilan Paranagama +5 more
2022Acta Haematologica9 citations Open access
Semantic Scholar
SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis
H. Chifotides, L. Masarova, S. Verstovsek
2023Clinical Lymphoma, Myeloma & Leukemia8 citations Open access
Semantic Scholar
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis
L. Masarova, S. Verstovsek, F. Palandri, R. Mesa +9 more
2025Future Oncology7 citations Open access
Semantic Scholar
Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis
J. Mascarenhas, P. Bose, H. Hou, Wojciech Homenda +12 more
2024Blood7 citations
Semantic Scholar
Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): Post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2).
R. Mesa, F. Palandri, S. Verstovsek, L. Masarova +10 more
2023Journal of Clinical Oncology7 citations
Semantic Scholar
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera
I. Krečak, M. Skelin, S. Verstovsek
2023Expert Review of Hematology6 citations
Semantic Scholar
Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)‐I study
H. Kosiorek, R. Scherber, H. Geyer, S. Verstovsek +9 more
2022British Journal of Haematology6 citations
Semantic Scholar
Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.
S. Verstovsek, J. Kiladjian, A. Vannucchi, Jay Patel +17 more
2025NEJM Evidence5 citations
Semantic Scholar
P1024: MYLOX-1: A PHASE II STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR GB2064 (WITH FOCUS ON BONE MARROW COLLAGEN) IN PATIENTS WITH MYELOFIBROSIS
C. Harrison, J. Mascarenhas, D. Cilloni, R. Schlenk +7 more
2023HemaSphere5 citations Open access
Semantic Scholar
Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations
Mehrnoosh Tashakori, J. Khoury, M. Routbort, K. Patel +13 more
2022Modern Pathology5 citations Open access
Semantic Scholar
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
A. Gerds, R. Lyons, Philomena M. Colucci, Patricia Kalafut +2 more
2022Clinical Lymphoma, Myeloma & Leukemia5 citations Open access
Semantic Scholar
Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24
J. Mascarenhas, M. Kremyanskaya, A. Patriarca, V MNSSVKR GUPTA +13 more
2022Blood5 citations Open access
Semantic Scholar
MPN-141 Retrospective Comparison of Patient Outcomes on Pacritinib Versus Ruxolitinib in Patients With Myelofibrosis and Thrombocytopenia.
C. Harrison, P. Bose, R. Mesa, A. Gerds +10 more
2022Clinical Lymphoma, Myeloma & Leukemia5 citations
Semantic Scholar
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial
S. Verstovsek, M. Talpaz, M. Wadleigh, A. Isidori +13 more
2024Haematologica4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Kiladjian×18
Invite
J. Kiladjian — researcher profile on SciRah
A. Vannucchi×14
Invite
A. Vannucchi — researcher profile on SciRah
P. Bose×12
Invite
P. Bose — researcher profile on SciRah
J. Mascarenhas×12
Invite
J. Mascarenhas — researcher profile on SciRah

×12

Invite

A. Gerds — researcher profile on SciRah

V MNSSVKR GUPTA×11

Invite

V MNSSVKR GUPTA — researcher profile on SciRah

Invite

R. Mesa — researcher profile on SciRah

Stephen T. Oh×10

Invite

Stephen T. Oh — researcher profile on SciRah

L. Masarova×10

Invite

L. Masarova — researcher profile on SciRah

Invite

C. Harrison — researcher profile on SciRah

N. Pemmaraju×9

Invite

N. Pemmaraju — researcher profile on SciRah

Invite

C. Harrison — researcher profile on SciRah